To receive CME credit for this program:
- Read the CME information and mark the checkbox confirming you have read the disclosures to download the PDF file below
- Review the article and illustration
- Login or register at the CME post test website (http://www.bucmetest.com)
- Locate the course code I.ANG11TOL and take the test
Jointly sponsored by Boston University School of Medicine and the Angiogenesis Foundation
ACCREDITATION STATEMENT
This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through Joint Sponsorship of Boston University School of Medicine and the Angiogenesis Foundation. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Boston University School of Medicine designates this Internet activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit will be awarded provided this activity is used and completed according to instructions and a score of 70% or better is achieved. A certificate of credit will be issued to those who successfully complete the examination.
RELEASE AND EXPIRATION
Date of original release: December 30, 2011
Date of expiration: December, 2012
Estimated Time To Complete: 1.5 Hours
CME Course Code: I.ANG11TOL
TARGET AUDIENCE
Practicing oncologists in the U.S., researchers and medical students
HEALTHCARE GAP
Antiangiogenic agents that interfere with specific molecular targets (typically proteins and their receptors) involved in tumor growth and progression have become an important part of anticancer treatment strategies. The targets of antiangiogenic agents can include growth factor receptors, signaling molecules, cell-cycle proteins, modulators of apoptosis, and molecules involved in invasion and angiogenesis, which are essential for development and homeostasis in normal tissues. Despite the selectivity of novel targeted therapies, a range of previously unknown and sometimes unpredictable side effects can emerge. These can include “on-target” effects—inhibition of the protein or receptor for which the drug is intended—or “off-target” effects, which result from inhibition of proteins or receptors for which the drug is not specifically intended.
Although most of the side effects can be tolerated or managed, a sizeable percentage of patients develop more serious side effects requiring dose and frequency reductions or treatment discontinuation. The long-term impact of the most common serious side effects observed in clinical trials evaluating angioenesis inhibitors are a concern in cancer management. Cancer patients are living longer and receiving chronic sequential or combination therapy with a number of agents. An independent survey, “Educational Materials 2007” showed that 77.4% of clinicians see side effects as one of the leading factors considered when deciding which treatment strategy to use. While the majority of these side effects are easily managed through standard treatments, they require prompt recognition and intervention, often with the consult of a specialist. Further, most oncologists practicing today received their medical oncology training before the era of targeted therapies. There is therefore a critical need for a comprehensive, evidence-based, up-to-date review of the major classes of side effects of antiangiogenic agents, as these agents are now part of standard therapy for the major cancer types.
PROGRAM LEARNING OBJECTIVES
At the completion of this activity, participants should be able to:
- Describe the role of tumor angiogenesis as both a disease mechanism and therapeutic target in cancer.
- Explain the biological mechanisms of adverse effects underlying the major classes of angiogenesis inhibitors.
- Discuss recent safety data from clinical trials on antiangiogenic therapies for cancer, including both prospective and retrospective studies.
- Describe the management of the most common side effects of angiogenesis inhibitors.
- Explain strategies for minimizing toxicities and treatment interruptions for patients receiving these agents.
METHOD OF PARTICIPATION
There are no fees for participating in and receiving credit for this online educational activity. The participant should, in order, read the objectives and faculty disclosures, review the educational content, answer the multiple-choice post-test and complete the evaluation. This program is available in PDF format accessible from the Angiogenesis Foundation's website (http://www.angio.org) in the CME section. A print version is also available; for more information contact outreach@angio.org. After reviewing the material, CME credits are available through the Boston University School of Medicine's website (http://www.bucmetest.com) by selecting the name of the program (registration required). Course code: I.ANG11TOL.
ACKNOWLEDGEMENT OF SUPPORT
This activity is supported by educational grants from Genentech.
COURSE FACULTY
Jean-Bernard Durand, M.D., FACP, FCCP, F.A.C.C.
Associate Professor
Department of Cardiology
University of Texas MD Anderson Cancer Center
Brian Rini, M.D., FACP
Department of Solid Tumor Oncology
Cleveland Clinic Taussig Cancer Institute
Glickman Urological Institute
Associate Professor of Medicine
Cleveland Clinic Lerner College of Medicine
DISCLOSURE
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
Jean-Bernard Durand, M.D., FACP, FCCP, F.A.C.C., University of Texas MD Anderson Cancer Center
Faculty
Dr. Durand has nothing to disclose with regard to commercial interests.
Brian Rini. M.D., FACP, Cleveland Clinic Taussig Cancer Institute
Faculty
Dr. Rini receives grant/research support from GlaxoSmithKline and Pfizer, and is a consultant for Aveo, Genentech, GlaxoSmithKline, and Pfizer.
William W. Li, M.D.,
President, the Angiogenesis Foundation, Editor-in-Chief
Dr. Li has nothing to disclose with regard to commercial interests.
Vickie R. Driver, DPM, M.S., FACFAS, Associate Professor of Surgery, Boston University School of Medicine
Course Director
Dr. Driver receives grant/research support from Baxter, Celleration, and 3M.
Jody Walker, M.S.
BUSM CME Program Manager
BUSM CME Program Manager has nothing to disclose with regard to commercial interests.
Roderick A. Smith, M.S.
Medical Writer, Program Manager, the Angiogenesis Foundation
Medical Writer, Program Manager has nothing to disclose with regard to commercial interests.
Joyce Carpenter, M.D.
Medical Writer.
Medical Writer has nothing to disclose with regard to commercial interests.
DISCUSSION OF UNLABELLED USE
This CME activity contains discussion of published and/or investigational use of: bevacizumab (Avastin®), dasatinib, erlotinib (Tarceva®), everolimus (RAD001; Afinitor®), sorafenib (Nexavar®), sunitinib (Sutent®), and temsirolimus (Toricel®).
PRIVACY POLICY
The Office of Continuing Medical Education adheres to Boston University’s Conditions of Use and Policy on Computing Ethics. <http://www.bu.edu/cme/policies/privacy_policy.html>
Data gathered from participants who participate in Boston University School of Medicine’s (BUSM) Continuing Medical Education Internet-Based CME program is confidential.
Individual identifiable information is not shared with outside parties. Cumulative data may be analyzed by CME personnel, and, upon occasion, by individuals external to BUSM CME in order to determine trends.
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLEY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKE NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.
TOPICS AND EDUCATIONAL CONTENT
Tolerability and management of side effects of antiangiogenic therapies:
- Biological mechanisms of action underlying adverse effects of angiogenesis inhibitors
- Descriptions of the major classes of agents and the side effects associated with them
- Safety data from recent prospective and retrospective clinical studies of targeted cancer therapies
- Identification and proper medical management of side effects
- Strategies for minimizing side effects and maintaining continuity of therapy
SYSTEM REQUIREMENTS
This educational program is available in PDF format. To view and print PDF files, you must have Adobe Reader installed on your computer. Most computers already have this software installed. If yours does not, you can download Adobe Reader free from the Adobe Web site: http://www.adobe.com.
If you have questions regarding certificates, please contact BUSM CME by email at cme@bu.edu or visit http://www.bu.edu/cme
For questions about this program, please contact the Angiogenesis Foundation at 617-401-2779 or outreach@angio.org.
Copyright 2011 by the Angiogenesis Foundation. All rights reserved.
|
